Axplora
Axplora is a premier API manufacturing partner to the world’s leading patient-centric pharmaceutical and biotechnology companies, envisioning itself as a reliable partner and agile explorer. The company is the result of the merger of Farmabios, Novasep, and PharmaZell, leveraging its combined expertise and manufacturing capabilities across nine industrial sites in Europe and India, and an R&D facility in the USA. The company is dedicated to delivering top-quality active ingredients on time and at scale, to the highest industry standards, with a mission to help pharmaceutical companies make critical medicines better, faster, and more sustainably. Axplora offers CDMO solutions to innovators for their small molecule and biomolecular active pharmaceutical ingredients, as well as products that address lifestyle-induced respiratory, inflammatory, and liver diseases. With its headquarters in Raubling (near Munich, Germany), Axplora employs 2,400 people worldwide.
With its strong presence in the Biotechnology, Health Care, Manufacturing, and Pharmaceutical industries, Axplora is positioned as a key player in the global pharmaceutical manufacturing landscape. While specific details regarding the company's founding date and last investment remain undisclosed, Axplora's amalgamation of industry leaders and its dedication to enhancing pharmaceutical production make it an intriguing prospect for potential venture capital investment.
There is no investment information
No recent news or press coverage available for Axplora.